HK1207633A1 - Benzimidazol.es as cns active agents cns - Google Patents

Benzimidazol.es as cns active agents cns

Info

Publication number
HK1207633A1
HK1207633A1 HK15108259.2A HK15108259A HK1207633A1 HK 1207633 A1 HK1207633 A1 HK 1207633A1 HK 15108259 A HK15108259 A HK 15108259A HK 1207633 A1 HK1207633 A1 HK 1207633A1
Authority
HK
Hong Kong
Prior art keywords
cns
benzimidazol
active agents
cns active
agents
Prior art date
Application number
HK15108259.2A
Other languages
English (en)
Chinese (zh)
Inventor
西蒙娜‧
‧切卡雷利
拉維‧姚高希亞
羅蘭‧雅各布-勒特
于爾根‧維希曼
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1207633A1 publication Critical patent/HK1207633A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK15108259.2A 2012-10-01 2015-08-25 Benzimidazol.es as cns active agents cns HK1207633A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12186784 2012-10-01
PCT/EP2013/070166 WO2014053409A1 (fr) 2012-10-01 2013-09-27 Benzimidazoles en tant qu'agents actifs sur le snc

Publications (1)

Publication Number Publication Date
HK1207633A1 true HK1207633A1 (en) 2016-02-05

Family

ID=47044852

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108259.2A HK1207633A1 (en) 2012-10-01 2015-08-25 Benzimidazol.es as cns active agents cns

Country Status (11)

Country Link
US (1) US9365550B2 (fr)
EP (1) EP2903980B1 (fr)
JP (1) JP5947465B2 (fr)
KR (1) KR101676212B1 (fr)
CN (1) CN104703981B (fr)
BR (1) BR112015004942A2 (fr)
CA (1) CA2882525A1 (fr)
HK (1) HK1207633A1 (fr)
MX (1) MX2015002398A (fr)
RU (1) RU2647585C2 (fr)
WO (1) WO2014053409A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3344039A4 (fr) * 2015-09-03 2019-08-28 Arizona Board of Regents on behalf of the University of Arizona Petites molécules inhibitrices de dyrk1a et leurs utilisations
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
JPWO2018221728A1 (ja) 2017-06-02 2020-04-02 富士フイルム富山化学株式会社 アルツハイマー型認知症予防または治療剤
US11951092B2 (en) 2017-06-02 2024-04-09 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating brain atrophy
KR20200003102A (ko) 2017-06-02 2020-01-08 후지필름 도야마 케미컬 가부시키가이샤 아밀로이드 β 단백질량 감소제
AU2018277981B2 (en) 2017-06-02 2021-04-08 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating spinocerebellar ataxia
US20190060109A1 (en) * 2017-08-31 2019-02-28 Gregory Todd Johnson Method of Preventing Traumatic Brain Injury (TBI)
US11548878B2 (en) 2017-10-30 2023-01-10 Fujifilm Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof
EP4069685A1 (fr) * 2019-12-02 2022-10-12 F. Hoffmann-La Roche AG Inhibiteurs d'alcynyle- (hétéroaryl)-carboxamide hcn1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100297445B1 (ko) * 1995-04-21 2001-10-25 페더 벨링 벤즈이미다졸화합물및감마-아미노부틸산수용체복합체의조절인자로서의그들의용도
US7074801B1 (en) * 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
AU2006227729B2 (en) * 2005-03-16 2011-10-13 Aventis Pharmaceuticals Inc. Dipyrazoles as central nervous system agents
CN101351461B (zh) * 2005-12-27 2011-09-07 弗·哈夫曼-拉罗切有限公司 芳基-异*唑-4-基-咪唑衍生物
US7932399B2 (en) * 2006-01-24 2011-04-26 Janssen Pharmaceutica Nv 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS)
TWI391381B (zh) * 2006-03-24 2013-04-01 Neurosearch As 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途
WO2008016123A1 (fr) * 2006-08-03 2008-02-07 Takeda Pharmaceutical Company Limited INHIBITEUR DE LA GSK-3β
WO2008046072A2 (fr) 2006-10-13 2008-04-17 The Board Of Regents Of The University Of Texas System Inducteurs chimiques de la neurogénèse
JP2009292782A (ja) * 2008-06-06 2009-12-17 Asahi Kasei Pharma Kk 神経新生及び／又は神経再生促進剤
ES2487616T3 (es) * 2009-03-10 2014-08-22 Takeda Pharmaceutical Company Limited Derivados de benzofurano
CN103415289B (zh) 2010-07-07 2017-04-12 得克萨斯州大学系统董事会 前神经原性化合物

Also Published As

Publication number Publication date
EP2903980A1 (fr) 2015-08-12
JP5947465B2 (ja) 2016-07-06
CN104703981A (zh) 2015-06-10
KR101676212B1 (ko) 2016-11-14
RU2647585C2 (ru) 2018-03-16
KR20150047614A (ko) 2015-05-04
BR112015004942A2 (pt) 2017-07-04
US20150203472A1 (en) 2015-07-23
WO2014053409A1 (fr) 2014-04-10
US9365550B2 (en) 2016-06-14
EP2903980B1 (fr) 2017-07-19
RU2015112914A (ru) 2016-11-27
CA2882525A1 (fr) 2014-04-10
CN104703981B (zh) 2017-03-29
MX2015002398A (es) 2015-06-05
JP2015528486A (ja) 2015-09-28

Similar Documents

Publication Publication Date Title
TWI561171B (en) Active compound combinations
EP2814472A4 (fr) Agents réducteurs dithioamine
GB201304967D0 (en) .
EP2824297A4 (fr) Engin de construction
EP2826921A4 (fr) Machine de construction
EP2637901A4 (fr) Traversin actif
GB201204183D0 (en) .
HK1212625A1 (zh) 用於炎性疾病的抗- 、抗- 、抗- 、抗- 、抗- 和抗- 試劑
HK1207633A1 (en) Benzimidazol.es as cns active agents cns
EP2803830A4 (fr) Machine de construction
GB201216018D0 (en) Pharmacologically active compounds
EP2808519A4 (fr) Machine de construction
EP2808453A4 (fr) Engin de travaux publics
IL235908A (en) Disinfection system
EP2803832A4 (fr) Machine de construction
HK1202859A1 (en) Anti -malarial agents
IL239484A0 (en) Materials for omitting enterprise-tumor cells
ZA201408094B (en) Anti-malarial agents
HUE036048T2 (hu) Gyógyszerészetileg aktív vegyületek
RS55201B1 (sr) Antimalarijski agensi
GB201207370D0 (en) Active seat
GB201207426D0 (en) .
GB201206866D0 (en) .
GB201206865D0 (en) .
GB201205844D0 (en) .

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210926